Tag: Regeneron

Regeneron Agreed with Vyriad to Discover and Develop New Oncolytic Virus-Based Treatments of Cancer

regeneron
Regeneron Pharmaceuticals has entered into a research collaboration and option licensing agreement with Vyriad to discover and develop new oncolytic (cancer-killing) virus-based treatments for various...

Regeneron Pharmaceuticals Updated on Phase III Development Program of Libtayo®

regeneron
Regeneron Pharmaceuticals, Inc. provided an update on the ongoing Phase 3 development program evaluating Libtayo® (cemiplimab), a PD-1 inhibitor, as monotherapy and combination therapy in first-line p...

Regeneron and Sanofi Announced Positive Results from Two Phase 3 Trials Evaluating Dupixent®

regeneron
Regeneron Pharmaceuticals, Inc. and Sanofi announced that The Lancet has published detailed positive results from two Phase 3 trials evaluating the safety and efficacy of Dupixent® (dupilumab) in adul...

U.S. District Court Rules in Favor of Sanofi and Regeneron in Praluent® Patent Litigation

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for...

Regeneron Pharmaceuticals Announced Positive Pivotal Phase 3 Results for Evinacumab

regeneron
Regeneron Pharmaceuticals, Inc. announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholeste...

FDA Approved Regeneron’s EYLEA®

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA® (...

Regeneron and Sanofi Announced Positive Pivotal Phase 3 Trial of Dupixent®

clinical-trial
Regeneron Pharmaceuticals, Inc. and Sanofi announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and ...

FDA Approved Dupixent to Treat Adults with Nasal Polyps

The U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged infl...

Positive Phase 2 Results for IL-33 Antibody Announced by Sanofi and Regeneron

clinical-trial
Sanofi and Regeneron Pharmaceuticals, Inc. announced that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in...

Regeneron and Sanofi to Publish Updated Libtayo Data

cancer treatment
Regeneron Pharmaceuticals, Inc. and Sanofi announced that positive updated data for Libtayo® (cemiplimab-rwlc) in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) will be share...

FDA Approved Regeneron EYLEA

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby red...

Sanofi Dupixent Gained EU Approval

Sanofi and Regeneron’s Dupixent will now enter the asthma market in Europe, the new expansion confirming its blockbuster profile. The dual IL-4 and IL-13 inhibitor has just gained approval for the ...

EC Approved Dupixent for Severe Asthma

The European Commission has approved Dupixent® (dupilumab) for use in adults and adolescents 12 years and older as an addon maintenance treatment for severe asthma with type 2 inflammation characteriz...

Calixar Signed Exclusive Licensing Agreement With Regeneron

Calixar SAS (Calixar), a biotechnology company specialized in native membrane protein stabilization, announces today that it has entered into an exclusive licensing agreement with Regeneron Pharmaceut...

Sanofi and Regeneron Present Positive Opinion of CHMP for Asthma Treatment

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupi...

Sanofi and Regeneron Disagree Amgen to Keep Patents

Sanofi and Regeneron Pharmaceuticals Inc. announced they strongly disagree with certain aspects of jury verdict from the U.S. District Court for the District of Delaware. The jury upheld the validity ...